




RealRate

# PHARMACEUTICAL 2020

## Fulcrum Therapeutics Inc. Rank 156 of 358





RealRate

# PHARMACEUTICAL 2020

## Fulcrum Therapeutics Inc. Rank 156 of 358



The relative strengths and weaknesses of Fulcrum Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Fulcrum Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 78% points. The greatest weakness of Fulcrum Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 62% points.

The company's Economic Capital Ratio, given in the ranking table, is 101%, being 64% points above the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	100,083
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	12,140
Liabilities, Non-Current	55
Other Assets	1,151
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	11,091
Other Net Income	1,511
Other Revenues	29
Property and Equipment	9,205
Research and Development	71,072
Selling, General and Administrative Expense	13,145

Output Variable	Value in 1000 USD
Assets	110,439
Liabilities	23,286
Expenses	84,217
Revenues	29
Stockholders Equity	87,153
Net Income	-82,677
Comprehensive Net Income	-82,677
Economic Capital Ratio	101%